THTX Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of 42.95%. Theratechnologies, Inc.'s return on equity of -- beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Theratechnologies, Inc. has a consensus price target of $3.91, signalling upside risk potential of 14.55%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 5.15%. Given that Theratechnologies, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Theratechnologies, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Theratechnologies, Inc. has a beta of 0.286, which suggesting that the stock is 71.438% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Theratechnologies, Inc. quarterly revenues are $17.7M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Theratechnologies, Inc.'s net income of -$4.5M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.96x versus 8.41x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edesa Biotech, Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Theratechnologies, Inc. has a consensus price target of $3.91, signalling upside risk potential of 14.55%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $10.33 which suggests that it could grow by 532.18%. Given that Edesa Biotech, Inc. has higher upside potential than Theratechnologies, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Theratechnologies, Inc..

Theratechnologies, Inc. has a beta of 0.286, which suggesting that the stock is 71.438% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Theratechnologies, Inc. quarterly revenues are $17.7M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Theratechnologies, Inc.'s net income of -$4.5M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.96x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of -2178.51%. Theratechnologies, Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Theratechnologies, Inc. has a consensus price target of $3.91, signalling upside risk potential of 14.55%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 298.01%. Given that Lexaria Bioscience Corp. has higher upside potential than Theratechnologies, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Theratechnologies, Inc..

Theratechnologies, Inc. has a beta of 0.286, which suggesting that the stock is 71.438% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Theratechnologies, Inc. quarterly revenues are $17.7M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Theratechnologies, Inc.'s net income of -$4.5M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.96x versus 34.19x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Theratechnologies, Inc. has a consensus price target of $3.91, signalling upside risk potential of 14.55%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 452.37%. Given that Oncolytics Biotech, Inc. has higher upside potential than Theratechnologies, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Theratechnologies, Inc..

Theratechnologies, Inc. has a beta of 0.286, which suggesting that the stock is 71.438% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Theratechnologies, Inc. quarterly revenues are $17.7M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Theratechnologies, Inc.'s net income of -$4.5M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.96x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.